Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNR-068 vs Stelara in Moderate to Severe Plaque Psoriasis
NCT06488664Phase 3Completed
- Sponsor
- Generium
- Start
- Jul 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of ustekinumab in plaque psoriasis (2 arms), sponsored by Generium. Primary endpoint: Psoriasis Area and Severity Index 75% Improvement at 12 weeks. Started Jul 2023; status: completed.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06488664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06488664.